ID   BIRC6_HUMAN             Reviewed;        4857 AA.
AC   Q9NR09; Q9ULD1;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 3.
DT   18-JUN-2025, entry version 207.
DE   RecName: Full=Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6 {ECO:0000303|PubMed:36758104, ECO:0000303|PubMed:36758105, ECO:0000303|PubMed:36758106};
DE            EC=2.3.2.24 {ECO:0000269|PubMed:36758104, ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106};
DE   AltName: Full=BIR repeat-containing ubiquitin-conjugating enzyme {ECO:0000303|PubMed:14765125};
DE            Short=BRUCE {ECO:0000303|PubMed:14765125};
DE   AltName: Full=Baculoviral IAP repeat-containing protein 6;
DE   AltName: Full=Ubiquitin-conjugating BIR domain enzyme apollon {ECO:0000303|PubMed:10544019};
DE            Short=APOLLON {ECO:0000303|PubMed:10544019};
GN   Name=BIRC6; Synonyms=KIAA1289;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 29-4857.
RC   TISSUE=Brain;
RX   PubMed=10544019; DOI=10.1006/bbrc.1999.1585;
RA   Chen Z., Naito M., Hori S., Mashima T., Yamori T., Tsuruo T.;
RT   "A human IAP-family gene, apollon, expressed in human brain cancer cells.";
RL   Biochem. Biophys. Res. Commun. 264:847-854(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2063-4857.
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   INTERACTION WITH RNF41, UBIQUITINATION, AND FUNCTION.
RX   PubMed=14765125; DOI=10.1038/sj.emboj.7600075;
RA   Qiu X.B., Markant S.L., Yuan J., Goldberg A.L.;
RT   "Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway
RT   for triggering apoptosis.";
RL   EMBO J. 23:800-810(2004).
RN   [6]
RP   FUNCTION, SUBUNIT, ACTIVITY REGULATION, DOMAIN BIR, AND INTERACTION WITH
RP   HTRA2; CASP3; CASP6; CASP7; CASP9 AND DIABLO/SMAC.
RX   PubMed=15200957; DOI=10.1016/j.molcel.2004.05.018;
RA   Bartke T., Pohl C., Pyrowolakis G., Jentsch S.;
RT   "Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin
RT   ligase.";
RL   Mol. Cell 14:801-811(2004).
RN   [7]
RP   REVIEW ON FUNCTION.
RX   PubMed=15340445; DOI=10.1038/ncb0904-804;
RA   Martin S.J.;
RT   "An Apollon vista of death and destruction.";
RL   Nat. Cell Biol. 6:804-806(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION, UBIQUITINATION,
RP   DEUBIQUITINATION, AND INTERACTION WITH KIF23/MKLP1; USP8/UBPY;
RP   BIRC5/SURVIVIN; MAP2K1/MEK1; RAB8A/RAB8; RAB11A/RAB11; PLK1; EXOC3/SEC6 AND
RP   EXOC4/SEC8.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled by
RT   BRUCE.";
RL   Cell 132:832-845(2008).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=18414036; DOI=10.4161/cc.7.8.5783;
RA   Dubrez-Daloz L., Dupoux A., Cartier J.;
RT   "IAPs: more than just inhibitors of apoptosis proteins.";
RL   Cell Cycle 7:1036-1046(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480; SER-581; SER-590;
RP   SER-2222; SER-2955; THR-3931 AND SER-4023, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-480 AND THR-1710, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 4498-4820.
RG   Structural genomics consortium (SGC);
RT   "Ubc domain of the ubiquitin-protein ligase baculoviral IAP repeat-
RT   containing protein 6.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [20] {ECO:0007744|PDB:3CEG}
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 4498-4820.
RX   PubMed=22496338; DOI=10.1074/mcp.o111.013706;
RA   Sheng Y., Hong J.H., Doherty R., Srikumar T., Shloush J., Avvakumov G.V.,
RA   Walker J.R., Xue S., Neculai D., Wan J.W., Kim S.K., Arrowsmith C.H.,
RA   Raught B., Dhe-Paganon S.;
RT   "A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure-
RT   function screen.";
RL   Mol. Cell. Proteomics 11:329-341(2012).
RN   [21] {ECO:0007744|PDB:8E2D, ECO:0007744|PDB:8E2E, ECO:0007744|PDB:8E2F, ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2H, ECO:0007744|PDB:8E2I, ECO:0007744|PDB:8E2K}
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.98 ANGSTROMS) OF BIRC6 ALONE AND IN
RP   COMPLEX WITH DIABLO/SMAC; CASP3; CASP7 AND HTRA2 MUTANT A-306, FUNCTION,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, INTERACTION WITH DIABLO,
RP   AUTOUBIQUITINATION, PROTEOLYTIC CLEAVAGE, WD REPEATS, AND MUTAGENESIS OF
RP   CYS-328; CYS-331 AND 1616-ALA--ALA-1666.
RX   PubMed=36758104; DOI=10.1126/science.ade5750;
RA   Hunkeler M., Jin C.Y., Fischer E.S.;
RT   "Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated
RT   release of caspases.";
RL   Science 379:1105-1111(2023).
RN   [22] {ECO:0007744|PDB:8ATM, ECO:0007744|PDB:8ATO}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF BIRC6 ALONE AND IN
RP   COMPLEX WITH DIABLO, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION,
RP   SUBUNIT, INTERACTION WITH DIABLO, AUTOUBIQUITINATION, WD REPEATS, AND
RP   MUTAGENESIS OF ASP-342; HIS-351 AND 3189-HIS--ARG-3193.
RX   PubMed=36758106; DOI=10.1126/science.ade8840;
RA   Dietz L., Ellison C.J., Riechmann C., Cassidy C.K., Felfoldi F.D.,
RA   Pinto-Fernandez A., Kessler B.M., Elliott P.R.;
RT   "Structural basis for SMAC-mediated antagonism of caspase inhibition by the
RT   giant ubiquitin ligase BIRC6.";
RL   Science 379:1112-1117(2023).
RN   [23] {ECO:0007744|PDB:8ATU, ECO:0007744|PDB:8ATX, ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.30 ANGSTROMS) IN COMPLEX WITH ZINC;
RP   HTRA2 AND DIABLO, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION,
RP   SUBUNIT, INTERACTION WITH DIABLO, AUTOUBIQUITINATION, PROTEOLYTIC CLEAVAGE,
RP   WD REPEATS, AND MUTAGENESIS OF ASP-342; HIS-351; 2228-SER--THR-2295;
RP   3190-ARG--ARG-3193; 4094-VAL--SER-4145 AND CYS-4666.
RX   PubMed=36758105; DOI=10.1126/science.ade8873;
RA   Ehrmann J.F., Grabarczyk D.B., Heinke M., Deszcz L., Kurzbauer R.,
RA   Hudecz O., Shulkina A., Gogova R., Meinhart A., Versteeg G.A., Clausen T.;
RT   "Structural basis for regulation of apoptosis and autophagy by the
RT   BIRC6/SMAC complex.";
RL   Science 379:1117-1123(2023).
CC   -!- FUNCTION: Anti-apoptotic protein known as inhibitor of apoptosis (IAP)
CC       which can regulate cell death by controlling caspases and by acting as
CC       an E3 ubiquitin-protein ligase (PubMed:14765125, PubMed:15200957,
CC       PubMed:18329369). Unlike most IAPs, does not contain a RING domain and
CC       it is not a RING-type E3 ligase (PubMed:15200957, PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). Instead acts as a dual E2/E3 enzyme
CC       that combines ubiquitin conjugating (E2) and ubiquitin ligase (E3)
CC       activities in a single polypeptide (PubMed:15200957, PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). Ubiquitination is mediated by a non-
CC       canonical E1 ubiquitin activating enzyme UBA6 (PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). Ubiquitinates CASP3, CASP7 and CASP9
CC       and inhibits their caspase activity; also ubiquitinates their
CC       procaspases but to a weaker extent (PubMed:15200957, PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). Ubiquitinates pro-apoptotic factors
CC       DIABLO/SMAC and HTRA2 (PubMed:15200957, PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). DIABLO/SMAC antagonizes the caspase
CC       inhibition activity of BIRC6 by competing for the same binding sites as
CC       the caspases (PubMed:18329369, PubMed:36758106). Ubiquitinates the
CC       autophagy protein MAP1LC3B; this activity is also inhibited by
CC       DIABLO/SMAC (PubMed:36758105). Important regulator for the final stages
CC       of cytokinesis (PubMed:18329369). Crucial for normal vesicle targeting
CC       to the site of abscission, but also for the integrity of the midbody
CC       and the midbody ring, and its striking ubiquitin modification
CC       (PubMed:18329369). {ECO:0000269|PubMed:14765125,
CC       ECO:0000269|PubMed:15200957, ECO:0000269|PubMed:18329369,
CC       ECO:0000269|PubMed:36758104, ECO:0000269|PubMed:36758105,
CC       ECO:0000269|PubMed:36758106}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E1 ubiquitin-activating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E1 ubiquitin-activating enzyme]-L-
CC         cysteine + N(6)-monoubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.24; Evidence={ECO:0000269|PubMed:36758104,
CC         ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106};
CC   -!- ACTIVITY REGULATION: Inhibited by DIABLO/SMAC, which competes for the
CC       substrate-binding sites on BIRC6 (PubMed:15200957, PubMed:36758104,
CC       PubMed:36758105, PubMed:36758106). BIRC6 inhibits caspases and protease
CC       by ubiquitination but BIRC6 itself is subjected to protease cleavage by
CC       CASP3, CASP6, CASP7, CASP9 and HTRA2 by protease cleavage
CC       (PubMed:15200957, PubMed:36758104, PubMed:36758105).
CC       {ECO:0000269|PubMed:15200957, ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106}.
CC   -!- SUBUNIT: Homodimer; antiparallel (PubMed:36758104, PubMed:36758105,
CC       PubMed:36758106). Interacts with RNF41 (PubMed:14765125). Interacts
CC       with DIABLO/SMAC, likely with higher affinity to SMAC dimer than SMAC
CC       monomer; this interaction blocks the substrate-binding site and
CC       inhibits the caspase inhibition activity of BIRC6 (PubMed:15200957,
CC       PubMed:36758104, PubMed:36758105, PubMed:36758106). Interacts with
CC       KIF23/MKLP1, USP8/UBPY, BIRC5/survivin, MAP2K1/MEK1, RAB8A/RAB8,
CC       RAB11A/RAB11, PLK1, EXOC3/SEC6 and EXOC4/SEC8 (PubMed:18329369).
CC       {ECO:0000269|PubMed:14765125, ECO:0000269|PubMed:15200957,
CC       ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106}.
CC   -!- INTERACTION:
CC       Q9NR09; Q99996: AKAP9; NbExp=2; IntAct=EBI-1765160, EBI-1048311;
CC       Q9NR09; Q8ND61: C3orf20; NbExp=2; IntAct=EBI-1765160, EBI-53997188;
CC       Q9NR09; Q96A65: EXOC4; NbExp=3; IntAct=EBI-1765160, EBI-355383;
CC       Q9NR09; Q02241: KIF23; NbExp=4; IntAct=EBI-1765160, EBI-306852;
CC       Q9NR09; Q02750: MAP2K1; NbExp=2; IntAct=EBI-1765160, EBI-492564;
CC       Q9NR09; Q9H1P3: OSBPL2; NbExp=2; IntAct=EBI-1765160, EBI-2828285;
CC       Q9NR09; P53350: PLK1; NbExp=4; IntAct=EBI-1765160, EBI-476768;
CC       Q9NR09; Q86UB9: TMEM135; NbExp=2; IntAct=EBI-1765160, EBI-20841176;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi network membrane
CC       {ECO:0000269|PubMed:18329369}. Endosome {ECO:0000269|PubMed:18329369}.
CC       Cytoplasm, cytoskeleton, spindle pole {ECO:0000269|PubMed:18329369}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:18329369}. Midbody, Midbody ring
CC       {ECO:0000269|PubMed:18329369}. Note=Exhibits cell cycle-dependent
CC       localization. Concentrates in a pericentriolar compartment in
CC       interphase, moves partially to spindle poles in metaphase, and finally
CC       localizes to the spindle midzone and the midbody in telophase and
CC       during cytokinesis. On the midbody, localizes to the midbody ring, also
CC       called Flemming body (PubMed:18329369). In interphase cells, localizes
CC       to the trans-Golgi network membrane and endosomes. During cytokinesis,
CC       a fraction moves to the midzone where it specifically arrives at the
CC       midbody ring. After abscission completion, travels with the midbody
CC       remnant into one daughter cell, and remains bound to it until a new
CC       midbody ring is formed during the next cell division (PubMed:18329369).
CC       {ECO:0000269|PubMed:18329369}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain cancer cells.
CC   -!- DOMAIN: The BIR domain is essential for its anti-apoptotic function and
CC       is important for binding to DIABLO/SMAC and caspases.
CC       {ECO:0000269|PubMed:15200957, ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106}.
CC   -!- PTM: Ubiquitinated; mediated by RNF41 E3 ligase and leads to
CC       proteasomal degradation, impairing inhibition of apoptosis
CC       (PubMed:14765125). Deubiquitinated by USP8/UBPY (PubMed:18329369).
CC       Autoubiquitinated; mediated by E1 ubiquitin activating enzyme UBA6
CC       (PubMed:36758104, PubMed:36758105, PubMed:36758106).
CC       {ECO:0000269|PubMed:14765125, ECO:0000269|PubMed:18329369,
CC       ECO:0000269|PubMed:36758104, ECO:0000269|PubMed:36758105,
CC       ECO:0000269|PubMed:36758106}.
CC   -!- PTM: Proteolytically cleaved. Acts as substrate for CASP3, CASP6,
CC       CASP7, CASP9 and HTRA2. {ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105}.
CC   -!- SIMILARITY: Belongs to the BIRC6 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86603.2; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/798/BIRC6";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC079837; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133243; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133245; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133246; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF265555; AAF75772.1; -; mRNA.
DR   EMBL; AB033115; BAA86603.2; ALT_FRAME; mRNA.
DR   CCDS; CCDS33175.2; -.
DR   RefSeq; NP_057336.3; NM_016252.4.
DR   PDB; 3CEG; X-ray; 2.01 A; A/B=4498-4820.
DR   PDB; 8ATM; EM; 3.30 A; A/B=1-4857.
DR   PDB; 8ATO; EM; 3.00 A; A/B=1-4857.
DR   PDB; 8ATU; EM; 3.30 A; A/B=1-4857.
DR   PDB; 8ATX; EM; 7.00 A; A/B=1-4857.
DR   PDB; 8AUK; EM; 6.20 A; A/B=1-4857.
DR   PDB; 8AUW; EM; 7.20 A; A/B=1-4857.
DR   PDB; 8E2D; EM; 2.07 A; A/B=1-4857.
DR   PDB; 8E2E; EM; 1.98 A; A/B=1-4857.
DR   PDB; 8E2F; EM; 2.47 A; A=1-4857.
DR   PDB; 8E2G; EM; 2.99 A; A=1-4857.
DR   PDB; 8E2H; EM; 2.30 A; A=1-4857.
DR   PDB; 8E2I; EM; 3.04 A; A/B=1-4857.
DR   PDB; 8E2K; EM; 3.21 A; A/B=1-4857.
DR   PDBsum; 3CEG; -.
DR   PDBsum; 8ATM; -.
DR   PDBsum; 8ATO; -.
DR   PDBsum; 8ATU; -.
DR   PDBsum; 8ATX; -.
DR   PDBsum; 8AUK; -.
DR   PDBsum; 8AUW; -.
DR   PDBsum; 8E2D; -.
DR   PDBsum; 8E2E; -.
DR   PDBsum; 8E2F; -.
DR   PDBsum; 8E2G; -.
DR   PDBsum; 8E2H; -.
DR   PDBsum; 8E2I; -.
DR   PDBsum; 8E2K; -.
DR   EMDB; EMD-15648; -.
DR   EMDB; EMD-15650; -.
DR   EMDB; EMD-15651; -.
DR   EMDB; EMD-15652; -.
DR   EMDB; EMD-15653; -.
DR   EMDB; EMD-15654; -.
DR   EMDB; EMD-15663; -.
DR   EMDB; EMD-15668; -.
DR   EMDB; EMD-15672; -.
DR   EMDB; EMD-15675; -.
DR   EMDB; EMD-27832; -.
DR   EMDB; EMD-27833; -.
DR   EMDB; EMD-27834; -.
DR   EMDB; EMD-27835; -.
DR   EMDB; EMD-27836; -.
DR   EMDB; EMD-27837; -.
DR   EMDB; EMD-27839; -.
DR   EMDB; EMD-27840; -.
DR   EMDB; EMD-27841; -.
DR   SMR; Q9NR09; -.
DR   BioGRID; 121521; 281.
DR   FunCoup; Q9NR09; 5068.
DR   IntAct; Q9NR09; 125.
DR   MINT; Q9NR09; -.
DR   STRING; 9606.ENSP00000393596; -.
DR   MEROPS; I32.006; -.
DR   TCDB; 8.A.217.1.1; the apoptosis cell death regulator (acdr) family.
DR   GlyCosmos; Q9NR09; 1 site, 1 glycan.
DR   GlyGen; Q9NR09; 9 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites).
DR   iPTMnet; Q9NR09; -.
DR   PhosphoSitePlus; Q9NR09; -.
DR   SwissPalm; Q9NR09; -.
DR   BioMuta; BIRC6; -.
DR   DMDM; 313104079; -.
DR   jPOST; Q9NR09; -.
DR   MassIVE; Q9NR09; -.
DR   PaxDb; 9606-ENSP00000393596; -.
DR   PeptideAtlas; Q9NR09; -.
DR   ProteomicsDB; 82241; -.
DR   Pumba; Q9NR09; -.
DR   Antibodypedia; 29188; 216 antibodies from 31 providers.
DR   DNASU; 57448; -.
DR   Ensembl; ENST00000421745.7; ENSP00000393596.2; ENSG00000115760.16.
DR   GeneID; 57448; -.
DR   KEGG; hsa:57448; -.
DR   MANE-Select; ENST00000421745.7; ENSP00000393596.2; NM_016252.4; NP_057336.3.
DR   UCSC; uc010ezu.4; human.
DR   AGR; HGNC:13516; -.
DR   CTD; 57448; -.
DR   DisGeNET; 57448; -.
DR   GeneCards; BIRC6; -.
DR   HGNC; HGNC:13516; BIRC6.
DR   HPA; ENSG00000115760; Low tissue specificity.
DR   MalaCards; BIRC6; -.
DR   MIM; 605638; gene.
DR   OpenTargets; ENSG00000115760; -.
DR   VEuPathDB; HostDB:ENSG00000115760; -.
DR   eggNOG; KOG0895; Eukaryota.
DR   eggNOG; KOG1101; Eukaryota.
DR   GeneTree; ENSGT00940000156126; -.
DR   HOGENOM; CLU_000111_1_0_1; -.
DR   InParanoid; Q9NR09; -.
DR   OMA; TTWDEHV; -.
DR   OrthoDB; 2196114at2759; -.
DR   PAN-GO; Q9NR09; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9NR09; -.
DR   PathwayCommons; Q9NR09; -.
DR   Reactome; R-HSA-9700645; ALK mutants bind TKIs.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   SignaLink; Q9NR09; -.
DR   SIGNOR; Q9NR09; -.
DR   BioGRID-ORCS; 57448; 223 hits in 1208 CRISPR screens.
DR   ChiTaRS; BIRC6; human.
DR   EvolutionaryTrace; Q9NR09; -.
DR   GeneWiki; BIRC6; -.
DR   GenomeRNAi; 57448; -.
DR   Pharos; Q9NR09; Tbio.
DR   PRO; PR:Q9NR09; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NR09; protein.
DR   Bgee; ENSG00000115760; Expressed in epithelial cell of pancreas and 196 other cell types or tissues.
DR   ExpressionAtlas; Q9NR09; baseline and differential.
DR   GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0090543; C:Flemming body; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0060711; P:labyrinthine layer development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:UniProtKB.
DR   CDD; cd00022; BIR; 1.
DR   CDD; cd23810; UBCc_BIRC6; 1.
DR   FunFam; 3.10.110.10:FF:000014; Baculoviral IAP repeat-containing protein 6; 1.
DR   FunFam; 1.10.1170.10:FF:000001; baculoviral IAP repeat-containing protein 6 isoform X1; 1.
DR   Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1.
DR   Gene3D; 3.10.110.10; Ubiquitin Conjugating Enzyme; 1.
DR   IDEAL; IID00636; -.
DR   InterPro; IPR001370; BIR_rpt.
DR   InterPro; IPR022103; BIRC6.
DR   InterPro; IPR000608; UBQ-conjugat_E2_core.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   PANTHER; PTHR46116; (E3-INDEPENDENT) E2 UBIQUITIN-CONJUGATING ENZYME; 1.
DR   PANTHER; PTHR46116:SF39; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 6; 1.
DR   Pfam; PF00653; BIR; 1.
DR   Pfam; PF12356; BIRC6; 1.
DR   Pfam; PF00179; UQ_con; 1.
DR   SMART; SM00238; BIR; 1.
DR   SMART; SM00212; UBCc; 1.
DR   SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1.
DR   SUPFAM; SSF54495; UBC-like; 1.
DR   PROSITE; PS50143; BIR_REPEAT_2; 1.
DR   PROSITE; PS50127; UBC_2; 1.
DR   neXtProt; NX_Q9NR09; -.
DR   PharmGKB; PA25363; -.
DR   TreeFam; TF105357; -.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Cell cycle; Cell division; Cytoplasm;
KW   Cytoskeleton; Endosome; Golgi apparatus; Membrane; Metal-binding; Mitosis;
KW   Phosphoprotein; Protease inhibitor; Proteomics identification;
KW   Reference proteome; Repeat; Thiol protease inhibitor; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; WD repeat; Zinc.
FT   CHAIN           1..4857
FT                   /note="Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-
FT                   protein ligase BIRC6"
FT                   /id="PRO_0000122361"
FT   REPEAT          68..106
FT                   /note="WD 1"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          107..136
FT                   /note="WD 2"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          268..377
FT                   /note="BIR"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106"
FT   REPEAT          379..426
FT                   /note="WD 3"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          501..720
FT                   /note="WD 4"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          730..850
FT                   /note="WD 5"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          851..927
FT                   /note="WD 6"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   REPEAT          928..966
FT                   /note="WD 7"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8E2G, ECO:0007744|PDB:8E2I"
FT   DOMAIN          3819..4068
FT                   /note="Ubiquitin-like"
FT                   /evidence="ECO:0000269|PubMed:36758104,
FT                   ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106,
FT                   ECO:0007744|PDB:8ATM, ECO:0007744|PDB:8ATU,
FT                   ECO:0007744|PDB:8E2D"
FT   DOMAIN          4573..4740
FT                   /note="UBC core"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00388"
FT   REGION          465..498
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          579..618
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          984..1004
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1053..1073
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2945..2973
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3189..3193
FT                   /note="HRRAR loop; important for DIABLO/SMAC and HTRA2
FT                   binding"
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0000269|PubMed:36758106, ECO:0007744|PDB:8ATO,
FT                   ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW"
FT   REGION          3923..3949
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4260..4283
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4835..4857
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        472..482
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        579..588
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        595..618
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        992..1004
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1056..1065
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4261..4283
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4844..4857
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        4666
FT                   /note="Glycyl thioester intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00388"
FT   BINDING         328
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0007744|PDB:8ATU, ECO:0007744|PDB:8ATX,
FT                   ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW"
FT   BINDING         331
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0007744|PDB:8ATU, ECO:0007744|PDB:8ATX,
FT                   ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW"
FT   BINDING         348
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0007744|PDB:8ATU, ECO:0007744|PDB:8ATX,
FT                   ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW"
FT   BINDING         355
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0007744|PDB:8ATU, ECO:0007744|PDB:8ATX,
FT                   ECO:0007744|PDB:8AUK, ECO:0007744|PDB:8AUW"
FT   MOD_RES         473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88738"
FT   MOD_RES         480
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         482
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88738"
FT   MOD_RES         581
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         590
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1710
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2955
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         3931
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         4023
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MUTAGEN         328
FT                   /note="C->S: Impairs ubiquitination of CASP3, CASP7 and
FT                   HTRA2 mutant 'A-306'; when associated with S-331. Abolishes
FT                   interaction with DIABLO/SMAC and impairs ubiquitination of
FT                   DIABLO/SMAC; when associated with S-331 and 1616-A--A-1666
FT                   del."
FT                   /evidence="ECO:0000269|PubMed:36758104"
FT   MUTAGEN         331
FT                   /note="C->S: Impairs ubiquitination of CASP3, CASP7 and
FT                   HTRA2 mutant 'A-306'; when associated with S-328. Abolishes
FT                   interaction with DIABLO/SMAC and impairs ubiquitination of
FT                   DIABLO/SMAC; when associated with S-328 and 1616-A--A-1666
FT                   del."
FT                   /evidence="ECO:0000269|PubMed:36758104"
FT   MUTAGEN         342
FT                   /note="D->A: Abolishes interaction with CASP3 and the
FT                   caspase inhibition activity on CASP3. Impairs interaction
FT                   with CASP7 and abolishes the caspase inhibition activity on
FT                   CASP7. Abolishes interaction with CASP9. Abolishes
FT                   interaction with monomeric DIABLO/SMAC 'D-81' mutant.
FT                   Abolishes interaction with N-degron peptide from
FT                   DIABLO/SMAC."
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0000269|PubMed:36758106"
FT   MUTAGEN         342
FT                   /note="D->Q: Fails to ubiquitinate N-degron peptide from
FT                   HTRA2. Impairs DIABLO/SMAC inhibition on the ubiquitination
FT                   of MAP1LC3B by BIRC6. Enhances ubiquitination of
FT                   DIABLO/SMAC. Impairs interaction with DIABLO/SMAC; when
FT                   associated with H-351. Severely impairs DIABLO/SMAC
FT                   inhibition on the ubiquitination of MAP1LC3B by BIRC6; when
FT                   associated with 2228-S--T-2295 del and 3190-A--A-3193.
FT                   Enhances ubiquitination of DIABLO/SMAC; when associated
FT                   with 2228-S--T-2295 del and 3190-A--A-3193."
FT                   /evidence="ECO:0000269|PubMed:36758105"
FT   MUTAGEN         351
FT                   /note="H->D: Impairs interaction with CASP3 and abolishes
FT                   the caspase inhibition activity on CASP3. Impairs
FT                   interaction with CASP7 but has little effect on the caspase
FT                   inhibition activity on CASP7. Impairs interaction with
FT                   CASP9. Impairs interaction with monomeric DIABLO/SMAC
FT                   'D-81' mutant. Impairs interaction with N-degron peptide
FT                   from DIABLO/SMAC. Impairs interaction with DIABLO/SMAC;
FT                   when associated with A-342."
FT                   /evidence="ECO:0000269|PubMed:36758105,
FT                   ECO:0000269|PubMed:36758106"
FT   MUTAGEN         1616..1666
FT                   /note="Missing: Slightly impairs interaction with
FT                   DIABLO/SMAC. Abolishes interaction with DIABLO/SMAC and
FT                   impairs ubiquitination of DIABLO/SMAC; when associated with
FT                   S-328 and S-331."
FT                   /evidence="ECO:0000269|PubMed:36758104"
FT   MUTAGEN         2228..2295
FT                   /note="Missing: Impairs DIABLO/SMAC inhibition on the
FT                   ubiquitination of MAP1LC3B by BIRC6. Enhances
FT                   ubiquitination of DIABLO/SMAC. Severely impairs DIABLO/SMAC
FT                   inhibition on the ubiquitination of MAP1LC3B by BIRC6; when
FT                   associated with Q-342 and 3190-A--A-3193. Enhances
FT                   ubiquitination of DIABLO/SMAC; when associated with Q-342
FT                   and 3190-A--A-3193."
FT                   /evidence="ECO:0000269|PubMed:36758105"
FT   MUTAGEN         3189..3193
FT                   /note="HRRAR->AAAAA: Impairs interaction with monomeric
FT                   DIABLO/SMAC 'D-81' mutant."
FT                   /evidence="ECO:0000269|PubMed:36758106"
FT   MUTAGEN         3189..3193
FT                   /note="HRRAR->DDDDD: Impairs interaction with CASP7 and
FT                   mildly impairs the caspase inhibition activity on CASP7.
FT                   Impairs interaction with monomeric DIABLO/SMAC 'D-81'
FT                   mutant. Impairs interaction with DIABLO/SMAC; when
FT                   associated with A-342. Abolishes interaction with monomeric
FT                   DIABLO/SMAC 'D-81' mutant; when associated with A-342."
FT                   /evidence="ECO:0000269|PubMed:36758106"
FT   MUTAGEN         3190..3193
FT                   /note="RRAR->AAAA: No effect on DIABLO/SMAC inhibition on
FT                   the ubiquitination of MAP1LC3B by BIRC6. No effect on
FT                   ubiquitination of DIABLO/SMAC. Severely impairs DIABLO/SMAC
FT                   inhibition on the ubiquitination of MAP1LC3B by BIRC6; when
FT                   associated with Q-342 and 2228-S--T-2295 del. Enhances
FT                   ubiquitination of DIABLO/SMAC; when associated with Q-342
FT                   and 2228-S--T-2295 del."
FT                   /evidence="ECO:0000269|PubMed:36758105"
FT   MUTAGEN         4094..4145
FT                   /note="Missing: Impairs MAP1LC3B ubiquitination without
FT                   disrupting HTRA2 ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:36758105"
FT   MUTAGEN         4666
FT                   /note="C->A: Catalytically inactive; fails to
FT                   autoubiquitinate in the presence of UBA6."
FT                   /evidence="ECO:0000269|PubMed:36758105"
FT   CONFLICT        2319
FT                   /note="L -> F (in Ref. 3; BAA86603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2674
FT                   /note="T -> S (in Ref. 2; AAF75772)"
FT                   /evidence="ECO:0000305"
FT   STRAND          74..76
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            77..80
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          81..85
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          91..95
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            96..98
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          101..105
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            121..124
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          125..129
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          134..137
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            147..150
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          159..166
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           167..178
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           189..203
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           213..216
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          218..224
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           225..242
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           248..262
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           280..282
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           286..292
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           306..311
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          314..316
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          326..328
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            329..331
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           344..351
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            356..360
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           368..372
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          380..383
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          388..390
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          400..404
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          407..413
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            414..417
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          419..425
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           431..436
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          504..513
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          566..574
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          626..634
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          716..721
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   HELIX           725..728
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          731..738
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          740..751
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          823..829
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          844..849
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          912..916
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            917..920
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          921..925
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          940..945
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            947..949
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          951..956
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   STRAND          961..965
FT                   /evidence="ECO:0007829|PDB:8E2G"
FT   TURN            1012..1014
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1019..1027
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1031..1033
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1039..1041
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1046..1048
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1051..1054
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1056..1058
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1061..1066
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1070..1072
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1074..1079
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            1083..1086
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1089..1094
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1101..1110
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1120..1126
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1172..1176
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1178..1180
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1181..1187
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1188..1191
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1199..1203
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1206..1209
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1219..1226
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1292..1295
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1296..1306
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1314..1323
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1325..1335
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1340..1342
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1346..1363
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1377..1383
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1385..1394
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1398..1413
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1424..1435
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1436..1441
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1445..1458
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            1459..1462
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1463..1483
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1487..1495
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1562..1565
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1569..1574
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1578..1580
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1777..1781
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            1784..1786
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1788..1806
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1812..1822
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           1824..1827
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1829..1835
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            1837..1839
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1842..1844
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1852..1862
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1871..1874
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          1877..1883
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            1886..1888
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2012..2017
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2020..2040
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            2046..2048
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   STRAND          2049..2055
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2056..2066
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            2067..2069
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2072..2086
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2092..2104
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2114..2127
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   TURN            2128..2130
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2133..2146
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2147..2149
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2165..2181
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2326..2340
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2348..2364
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2569..2573
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           2577..2598
FT                   /evidence="ECO:0007829|PDB:8E2F"
FT   HELIX           3429..3440
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3446..3468
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3484..3487
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3491..3506
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3513..3516
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3519..3531
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3537..3552
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3554..3564
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3607..3616
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3620..3628
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3631..3643
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3680..3694
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3697..3703
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   TURN            3706..3708
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3709..3719
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3753..3771
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3775..3789
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3807..3815
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          3821..3827
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3847..3849
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          3855..3861
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3866..3873
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          3966..3968
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   TURN            3971..3974
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           3983..3992
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          4000..4007
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4070..4076
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4079..4084
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4155..4164
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4170..4174
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4178..4188
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          4195..4197
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4209..4211
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4212..4222
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   STRAND          4226..4228
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4229..4241
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4243..4255
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4306..4331
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4360..4366
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4369..4377
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4382..4385
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4389..4403
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   TURN            4406..4408
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4409..4411
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4433..4454
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4474..4498
FT                   /evidence="ECO:0007829|PDB:8E2H"
FT   HELIX           4524..4533
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4536..4540
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4543..4545
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4551..4555
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4560..4564
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4572..4588
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4597..4604
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4608..4615
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4625..4631
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   TURN            4634..4638
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   STRAND          4642..4645
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   TURN            4649..4652
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4668..4670
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4677..4679
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   TURN            4683..4685
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4688..4698
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4704..4707
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4711..4714
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4718..4738
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4741..4745
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   TURN            4749..4751
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4752..4777
FT                   /evidence="ECO:0007829|PDB:3CEG"
FT   HELIX           4788..4810
FT                   /evidence="ECO:0007829|PDB:3CEG"
SQ   SEQUENCE   4857 AA;  530269 MW;  ACA0EB5B3EFBA0C0 CRC64;
     MVTGGGAAPP GTVTEPLPSV IVLSAGRKMA AAAAAASGPG CSSAAGAGAA GVSEWLVLRD
     GCMHCDADGL HSLSYHPALN AILAVTSRGT IKVIDGTSGA TLQASALSAK PGGQVKCQYI
     SAVDKVIFVD DYAVGCRKDL NGILLLDTAL QTPVSKQDDV VQLELPVTEA QQLLSACLEK
     VDISSTEGYD LFITQLKDGL KNTSHETAAN HKVAKWATVT FHLPHHVLKS IASAIVNELK
     KINQNVAALP VASSVMDRLS YLLPSARPEL GVGPGRSVDR SLMYSEANRR ETFTSWPHVG
     YRWAQPDPMA QAGFYHQPAS SGDDRAMCFT CSVCLVCWEP TDEPWSEHER HSPNCPFVKG
     EHTQNVPLSV TLATSPAQFP CTDGTDRISC FGSGSCPHFL AAATKRGKIC IWDVSKLMKV
     HLKFEINAYD PAIVQQLILS GDPSSGVDSR RPTLAWLEDS SSCSDIPKLE GDSDDLLEDS
     DSEEHSRSDS VTGHTSQKEA MEVSLDITAL SILQQPEKLQ WEIVANVLED TVKDLEELGA
     NPCLTNSKSE KTKEKHQEQH NIPFPCLLAG GLLTYKSPAT SPISSNSHRS LDGLSRTQGE
     SISEQGSTDN ESCTNSELNS PLVRRTLPVL LLYSIKESDE KAGKIFSQMN NIMSKSLHDD
     GFTVPQIIEM ELDSQEQLLL QDPPVTYIQQ FADAAANLTS PDSEKWNSVF PKPGTLVQCL
     RLPKFAEEEN LCIDSITPCA DGIHLLVGLR TCPVESLSAI NQVEALNNLN KLNSALCNRR
     KGELESNLAV VNGANISVIQ HESPADVQTP LIIQPEQRNV SGGYLVLYKM NYATRIVTLE
     EEPIKIQHIK DPQDTITSLI LLPPDILDNR EDDCEEPIED MQLTSKNGFE REKTSDISTL
     GHLVITTQGG YVKILDLSNF EILAKVEPPK KEGTEEQDTF VSVIYCSGTD RLCACTKGGE
     LHFLQIGGTC DDIDEADILV DGSLSKGIEP SSEGSKPLSN PSSPGISGVD LLVDQPFTLE
     ILTSLVELTR FETLTPRFSA TVPPCWVEVQ QEQQQRRHPQ HLHQQHHGDA AQHTRTWKLQ
     TDSNSWDEHV FELVLPKACM VGHVDFKFVL NSNITNIPQI QVTLLKNKAP GLGKVNALNI
     EVEQNGKPSL VDLNEEMQHM DVEESQCLRL CPFLEDHKED ILCGPVWLAS GLDLSGHAGM
     LTLTSPKLVK GMAGGKYRSF LIHVKAVNER GTEEICNGGM RPVVRLPSLK HQSNKGYSLA
     SLLAKVAAGK EKSSNVKNEN TSGTRKSENL RGCDLLQEVS VTIRRFKKTS ISKERVQRCA
     MLQFSEFHEK LLNTLCRKTD DGQITEHAQS LVLDTLCWLA GVHSNGPGSS KEGNENLLSK
     TRKFLSDIVR VCFFEAGRSI AHKCARFLAL CISNGKCDPC QPAFGPVLLK ALLDNMSFLP
     AATTGGSVYW YFVLLNYVKD EDLAGCSTAC ASLLTAVSRQ LQDRLTPMEA LLQTRYGLYS
     SPFDPVLFDL EMSGSSCKNV YNSSIGVQSD EIDLSDVLSG NGKVSSCTAA EGSFTSLTGL
     LEVEPLHFTC VSTSDGTRIE RDDAMSSFGV TPAVGGLSSG TVGEASTALS SAAQVALQSL
     SHAMASAEQQ LQVLQEKQQQ LLKLQQQKAK LEAKLHQTTA AAAAAASAVG PVHNSVPSNP
     VAAPGFFIHP SDVIPPTPKT TPLFMTPPLT PPNEAVSVVI NAELAQLFPG SVIDPPAVNL
     AAHNKNSNKS RMNPLGSGLA LAISHASHFL QPPPHQSIII ERMHSGARRF VTLDFGRPIL
     LTDVLIPTCG DLASLSIDIW TLGEEVDGRR LVVATDISTH SLILHDLIPP PVCRFMKITV
     IGRYGSTNAR AKIPLGFYYG HTYILPWESE LKLMHDPLKG EGESANQPEI DQHLAMMVAL
     QEDIQCRYNL ACHRLETLLQ SIDLPPLNSA NNAQYFLRKP DKAVEEDSRV FSAYQDCIQL
     QLQLNLAHNA VQRLKVALGA SRKMLSETSN PEDLIQTSST EQLRTIIRYL LDTLLSLLHA
     SNGHSVPAVL QSTFHAQACE ELFKHLCISG TPKIRLHTGL LLVQLCGGER WWGQFLSNVL
     QELYNSEQLL IFPQDRVFML LSCIGQRSLS NSGVLESLLN LLDNLLSPLQ PQLPMHRRTE
     GVLDIPMISW VVMLVSRLLD YVATVEDEAA AAKKPLNGNQ WSFINNNLHT QSLNRSSKGS
     SSLDRLYSRK IRKQLVHHKQ QLNLLKAKQK ALVEQMEKEK IQSNKGSSYK LLVEQAKLKQ
     ATSKHFKDLI RLRRTAEWSR SNLDTEVTTA KESPEIEPLP FTLAHERCIS VVQKLVLFLL
     SMDFTCHADL LLFVCKVLAR IANATRPTIH LCEIVNEPQL ERLLLLLVGT DFNRGDISWG
     GAWAQYSLTC MLQDILAGEL LAPVAAEAME EGTVGDDVGA TAGDSDDSLQ QSSVQLLETI
     DEPLTHDITG APPLSSLEKD KEIDLELLQD LMEVDIDPLD IDLEKDPLAA KVFKPISSTW
     YDYWGADYGT YNYNPYIGGL GIPVAKPPAN TEKNGSQTVS VSVSQALDAR LEVGLEQQAE
     LMLKMMSTLE ADSILQALTN TSPTLSQSPT GTDDSLLGGL QAANQTSQLI IQLSSVPMLN
     VCFNKLFSML QVHHVQLESL LQLWLTLSLN SSSTGNKENG ADIFLYNANR IPVISLNQAS
     ITSFLTVLAW YPNTLLRTWC LVLHSLTLMT NMQLNSGSSS AIGTQESTAH LLVSDPNLIH
     VLVKFLSGTS PHGTNQHSPQ VGPTATQAMQ EFLTRLQVHL SSTCPQIFSE FLLKLIHILS
     TERGAFQTGQ GPLDAQVKLL EFTLEQNFEV VSVSTISAVI ESVTFLVHHY ITCSDKVMSR
     SGSDSSVGAR ACFGGLFANL IRPGDAKAVC GEMTRDQLMF DLLKLVNILV QLPLSGNREY
     SARVSVTTNT TDSVSDEEKV SGGKDGNGSS TSVQGSPAYV ADLVLANQQI MSQILSALGL
     CNSSAMAMII GASGLHLTKH ENFHGGLDAI SVGDGLFTIL TTLSKKASTV HMMLQPILTY
     MACGYMGRQG SLATCQLSEP LLWFILRVLD TSDALKAFHD MGGVQLICNN MVTSTRAIVN
     TARSMVSTIM KFLDSGPNKA VDSTLKTRIL ASEPDNAEGI HNFAPLGTIT SSSPTAQPAE
     VLLQATPPHR RARSAAWSYI FLPEEAWCDL TIHLPAAVLL KEIHIQPHLA SLATCPSSVS
     VEVSADGVNM LPLSTPVVTS GLTYIKIQLV KAEVASAVCL RLHRPRDAST LGLSQIKLLG
     LTAFGTTSSA TVNNPFLPSE DQVSKTSIGW LRLLHHCLTH ISDLEGMMAS AAAPTANLLQ
     TCAALLMSPY CGMHSPNIEV VLVKIGLQST RIGLKLIDIL LRNCAASGSD PTDLNSPLLF
     GRLNGLSSDS TIDILYQLGT TQDPGTKDRI QALLKWVSDS ARVAAMKRSG RMNYMCPNSS
     TVEYGLLMPS PSHLHCVAAI LWHSYELLVE YDLPALLDQE LFELLFNWSM SLPCNMVLKK
     AVDSLLCSMC HVHPNYFSLL MGWMGITPPP VQCHHRLSMT DDSKKQDLSS SLTDDSKNAQ
     APLALTESHL ATLASSSQSP EAIKQLLDSG LPSLLVRSLA SFCFSHISSS ESIAQSIDIS
     QDKLRRHHVP QQCNKMPITA DLVAPILRFL TEVGNSHIMK DWLGGSEVNP LWTALLFLLC
     HSGSTSGSHN LGAQQTSARS ASLSSAATTG LTTQQRTAIE NATVAFFLQC ISCHPNNQKL
     MAQVLCELFQ TSPQRGNLPT SGNISGFIRR LFLQLMLEDE KVTMFLQSPC PLYKGRINAT
     SHVIQHPMYG AGHKFRTLHL PVSTTLSDVL DRVSDTPSIT AKLISEQKDD KEKKNHEEKE
     KVKAENGFQD NYSVVVASGL KSQSKRAVSA TPPRPPSRRG RTIPDKIGST SGAEAANKII
     TVPVFHLFHK LLAGQPLPAE MTLAQLLTLL YDRKLPQGYR SIDLTVKLGS RVITDPSLSK
     TDSYKRLHPE KDHGDLLASC PEDEALTPGD ECMDGILDES LLETCPIQSP LQVFAGMGGL
     ALIAERLPML YPEVIQQVSA PVVTSTTQEK PKDSDQFEWV TIEQSGELVY EAPETVAAEP
     PPIKSAVQTM SPIPAHSLAA FGLFLRLPGY AEVLLKERKH AQCLLRLVLG VTDDGEGSHI
     LQSPSANVLP TLPFHVLRSL FSTTPLTTDD GVLLRRMALE IGALHLILVC LSALSHHSPR
     VPNSSVNQTE PQVSSSHNPT STEEQQLYWA KGTGFGTGST ASGWDVEQAL TKQRLEEEHV
     TCLLQVLASY INPVSSAVNG EAQSSHETRG QNSNALPSVL LELLSQSCLI PAMSSYLRND
     SVLDMARHVP LYRALLELLR AIASCAAMVP LLLPLSTENG EEEEEQSECQ TSVGTLLAKM
     KTCVDTYTNR LRSKRENVKT GVKPDASDQE PEGLTLLVPD IQKTAEIVYA ATTSLRQANQ
     EKKLGEYSKK AAMKPKPLSV LKSLEEKYVA VMKKLQFDTF EMVSEDEDGK LGFKVNYHYM
     SQVKNANDAN SAARARRLAQ EAVTLSTSLP LSSSSSVFVR CDEERLDIMK VLITGPADTP
     YANGCFEFDV YFPQDYPSSP PLVNLETTGG HSVRFNPNLY NDGKVCLSIL NTWHGRPEEK
     WNPQTSSFLQ VLVSVQSLIL VAEPYFNEPG YERSRGTPSG TQSSREYDGN IRQATVKWAM
     LEQIRNPSPC FKEVIHKHFY LKRVEIMAQC EEWIADIQQY SSDKRVGRTM SHHAAALKRH
     TAQLREELLK LPCPEGLDPD TDDAPEVCRA TTGAEETLMH DQVKPSSSKE LPSDFQL
//
